Noopept
Russian-developed dipeptide nootropic. NGF + BDNF upregulator with reported cognitive + neuroprotective effects at sub-milligram doses.
This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.
N-phenylacetyl-L-prolylglycine ethyl ester. Russian Academy of Sciences synthesized in 1996; clinical use approved in Russia 2000. Active dose is ~1000× lower than piracetam (10-30 mg vs 1.6-4.8 g) because it crosses BBB efficiently and metabolizes to cycloprolylglycine (CPG), which mimics endogenous neurotrophin signaling. Small Russian RCTs in mild cognitive impairment + post-traumatic encephalopathy show modest cognitive improvement; Western trial data is sparse.
Distilled themes from named communities — Reddit threads, forums, creator commentary. Not direct quotes; not clinical evidence. Useful for calibrating expectations against what real self-experimenters report.
Cohort consensus: cleaner than racetams + faster onset (often within 30-60 min sublingual). Cycling required to avoid tolerance. Choline pairing optional — less consistently reported as needed than with piracetam.
Quality varies wildly by vendor — Russian-source medical-grade vs research-chemistry powder. Third-party HPLC verification is the only honest way to verify a vendor. Tolerance can develop within 8-12 weeks of daily use; community wisdom is to cycle 6 weeks on / 2 weeks off. Mild irritability + sleep disruption reported at high doses.
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Not FDA-approved in US — sold as research compound. Prescription medicine in Russia (Noopept brand) and some FSU states.